Laekna (HKG:2105) disclosed that the first patient was administered a dose of LAE102, a weight loss drug, during the Phase I clinical trial in China, according to a Wednesday filing on the Hong Kong bourse.
The drug aims to help weight loss by removing fat without affecting muscle mass.
Shares of the company rose nearly 6% in Wednesday's morning trade.
Price (HKD): $5.90, Change: $+0.32, Percent Change: +5.73%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments